AB INBEV 70.740 € (+1,46 %) TINC 10.580 € (-0,38 %) SYENSQO 80.250 € (+1,01 %) KBC ANCORA 96.400 € (+0,73 %) MELEXIS 60.500 € (-3,20 %) D'IETEREN GROUP 173.000 € (+2,31 %) ONWARD MEDICAL 2.410 € (-2,63 %) EVS 18.660 € (+0,54 %) NYXOAH 1.158 € (-0,69 %) LOTUS BAKERIES 12 660.000 € (+2,26 %) GIMV 47.250 € (+1,18 %) ARGENX SE 718.600 € (-1,99 %) ASCENCIO 53.100 € (+1,34 %) VGP 63.100 € (+0,64 %) KINEPOLIS GROUP 51.600 € (+0,19 %) ELIA GROUP 120.100 € (+0,33 %) HOME INVEST BE. 17.800 € (+0,56 %) RETAIL ESTATES 61.500 € (-1,60 %) SOLVAC 91.500 € (+0,55 %) PROXIMUS 5.730 € (0,00 %) CENERGY 23.360 € (+1,48 %) WDP 19.300 € (+0,52 %) ORANGE BELGIUM 22.200 € (+0,91 %) SOLVAY 24.720 € (-0,56 %) VIOHALCO 16.280 € (-1,09 %) ACKERMANS V.HAAREN 263.200 € (+0,46 %) SIPEF 110.600 € (+3,17 %) VASTNED 27.450 € (+0,18 %) AEDIFICA 62.000 € (+1,39 %) AGEAS 73.400 € (+1,24 %) UCB 197.900 € (-2,94 %) CIE BOIS SAUVAGE 277.000 € (-0,36 %) TESSENDERLO 20.000 € (-0,25 %) SHURGARD 22.500 € (+1,81 %) KBC 121.300 € (-0,45 %) CELYAD ONCOLOGY 0.220 € (+4,76 %) BPOST 1.128 € (+2,17 %) BEKAERT 39.350 € (+0,13 %) RECTICEL 12.740 € (+0,63 %) ECONOCOM GROUP 1.360 € (0,00 %) FAGRON 22.200 € (-0,89 %) VAN DE VELDE 29.500 € (+0,68 %) HYLORIS 4.200 € (+5,00 %) ONTEX GROUP 1.900 € (+3,04 %) IMMOBEL 17.950 € (-0,28 %) TITAN S.A. 47.340 € (+0,34 %) MONTEA 63.200 € (+1,44 %) AZELIS GROUP 13.200 € (+2,56 %) SOFINA 252.800 € (+1,94 %) TUBIZE-FIN 170.400 € (-1,56 %) WERELDHAVE BELGIUM 50.000 € (-0,79 %) DEME GROUP 173.000 € (+0,58 %) AGFA-GEVAERT 0.415 € (-0,12 %) COLRUYT 34.840 € (+1,16 %) XIOR 24.150 € (+1,05 %) BREDERODE 97.400 € (+0,62 %) BARCO 7.005 € (0,00 %) GBL 70.700 € (+1,36 %) JENSEN-GROUP 75.000 € (0,00 %) INCLUSIO SA/NV 15.800 € (+0,64 %)
AXA 42.010 € (+0,48 %)
SHELL PLC 45.950 € (+0,86 %)
KPN KON 3.897 € (+0,44 %)
ALSTOM 16.450 € (+3,39 %)
HAL TRUST 162.800 € (+0,37 %)
ING GROEP N.V. 30.100 € (+0,22 %)
MEDINCELL 26.580 € (-7,71 %)
AHOLD DEL 31.610 € (+0,73 %)
TOMTOM 3.820 € (+1,33 %)
PROSUS 35.895 € (+0,07 %)
ATOS GROUP 21.640 € (-1,64 %)
VALLOUREC 18.550 € (-0,11 %)
ARCELORMITTAL SA 56.440 € (-0,67 %)
ASM INTERNATIONAL 821.200 € (-6,30 %)
WORLDLINE 10.780 € (+0,54 %)
AMG 26.820 € (-4,96 %)
V LANSCHOT KEMPEN 62.500 € (-0,64 %)
SANOFI 70.740 € (-1,20 %)
VIRBAC 325.000 € (+2,52 %)
GROUPE SFPI 1.755 € (+0,29 %)
ABIVAX 76.950 € (-1,60 %)
ALTAREA 73.800 € (+2,22 %)
ASML HOLDING 1 509.600 € (-4,20 %)
EMEIS 10.100 € (+1,61 %)
ERAMET 37.240 € (-14,43 %)
EUROFINS SCIENT. 78.460 € (+1,03 %)
SECHE ENVIRONNEM. 66.900 € (-3,74 %)
LEGRAND 137.450 € (-1,54 %)
RENAULT 27.260 € (+1,56 %)
PERNOD RICARD 65.520 € (+4,90 %)
EUTELSAT COMMUNIC. 1.370 € (-2,94 %)
OCI 4.124 € (+0,68 %)
WOLTERS KLUWER 78.840 € (+2,18 %)
HUNYVERS 4.280 € (0,00 %)
TIKEHAU CAPITAL 16.100 € (-0,62 %)
KERING 210.000 € (-1,45 %)
LVMH 384.050 € (-0,12 %)
SOCIETE GENERALE 64.840 € (+1,04 %)
GTT 215.600 € (-0,46 %)
VALEO 13.640 € (+1,00 %)
HAFFNER ENERGY 0.770 € (-3,27 %)
CRCAM TOURAINE CCI 107.000 € (-2,28 %)
FORVIA 8.738 € (+2,20 %)
DBT 0.066 € (+10,00 %)
EXOSENS 57.000 € (-1,55 %)
CARVOLIX 5.220 € (-1,51 %)
IMPLANET 0.186 € (+15,53 %)
CAPGEMINI 119.300 € (+3,42 %)
UNILEVER 55.870 € (-0,34 %)
ECOSLOPS 0.950 € (+2,59 %)
BNP PARIBAS ACT.A 90.230 € (+0,16 %)
PULLUP ENTERTAIN 7.900 € (-0,50 %)
PUBLICIS GROUPE SA 100.950 € (+2,24 %)
CIBOX INTER A CTIV 0.013 € (-6,38 %)
TOTALENERGIES 79.890 € (+1,15 %)
ORANGE 13.880 € (+1,06 %)
CEGEDIM 10.660 € (-1,30 %)
BAM GROEP KON 11.530 € (-1,20 %)
SODEXO 55.150 € (+0,27 %)
ADYEN 932.400 € (+1,26 %) News Réglementées
|
15/09/2026 09:00
Original-Research: MHP Hotel AG (von NuWays AG): BuyOriginal-Research: MHP Hotel AG - from NuWays AG Classification of NuWays AG to MHP Hotel AG
H1 optics are worse than operations; chg. Following Friday's guidance cut, MHP released its H1 report yesterday, confirming the picture. In detail: H1 sales came in at € 99.3m (eNuW: € 98.3m), up 25% yoy. Growth was significantly carried by the new hotels (Conrad and Hyatt Vienna), which added € 17m, implying organic growth of 3.8%. Occupancy came in at 72.0%, ADR at € 219 and RevPAR at € 158. Mind you, the reported rate data is adjusted for Conrad only. The Andaz Vienna was rebranded to Hyatt Regency over Easter, which both disrupted Q2 trading and structurally lowers portfolio ADR, so like-for-like rate erosion is materially smaller than the reported 1% decline suggests. Margin looks worse than it is. H1 EBITDA of € 0.2m was only slightly behind eNuW of € 0.6m. The H1'25 € 2.3m figure is actually not a good comparable, as it was inflated by € 4.0m Conrad FF&E related one-offs. Hence, there is no cost problem as operating EBITDA improved by € 1.9m yoy. Slower Conrad ramp-up and Middle East cause guidance cut. While the sales guidance was only slightly cut to € 220-225m (old: c. € 225m), EBITDA was adjusted more significantly from c. € 10m to c. € 8m. The main reason for this is seen to be the Conrad, where occupancy ramp-up is running below budget as flows through the brand systems have not materialized yet. On top of this comes Middle East. Although accounting for only 2.5% of sales (FY25 base), these guests are the usual suite bookers and carry well above-average F&B spend, causing a disproportionate earnings hit. Energy adds to the pressure, not only on pure price but also higher consumption during the summer heat. The implied H2 run-rate of € 7.8m however seems reasonable, in our view, as H2 is seasonally the far stronger half, with events like Oktoberfest and EXPO REAL carrying Q3 and December now among the portfolio's strongest months on Christmas market demand. Overall, the case is intact, as the cut is largely a timing issue (Conrad), not structural. Besides this, the company remains the leading white-label operator in the DACH premium segment, with privileged access to high-barrier assets that come with limited capital commitment of its own. This allows the platform to add about 1,000 rooms by FY29e without touching the balance sheet. With premium demand structurally unbroken and the Conrad ramp-up a question of when rather than if, the earnings power of the enlarged portfolio should come through from FY27e onwards. At current levels, the market is not at all pricing this. Changes in estimates reflect the FY26 guidance adjustment as well as a more conservate approach on return to normal from Middle East travellers. We thus reiterate BUY with a new PT of € 3.50 (old: € 3.70) based on DCF. You can download the research here: mhp-hotel-ag-2026-09-15-previewreview-en-028fb For additional information visit our website: https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++ The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 2399172 15.09.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière